{"classes":[{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"-76081.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-40512.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-51199.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"c-KIT high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"-13480.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"-44973.7"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-48764.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-35678.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"c-KIT low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"-7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"FGF high trough concentration"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"FGF low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"78.3"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"15.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"45.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"PGF high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"5.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"28.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"PGF low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"2553.0"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-509.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-2708.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"TIE2 high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"1212.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"-1514.9"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-918.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-473.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"TIE2 low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"358.8"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"34.3"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-73.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-A high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"2436.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"18.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"52.3"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"39.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-A low trough concentration"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-C high trough concentration"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-C low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"88.0"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"139.7"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"187.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-D high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"423.2"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"44.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"153.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"90.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-D low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"-217.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"955.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-49.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGFR-1 high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"484.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"-67.2"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-7.7"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-741.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGFR-1 low trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"-2620.0"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-16136.9"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-16838.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGFR-2 high trough concentration"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"-12130.8"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"-7795.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG003","spread":"NA","value":"-8588.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"-10529.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGFR-2 low trough concentration"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"Participants with steady state trough concentration median levels for the following biomarker parameters (proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)) above the median levels were classified as high or below median levels were classified as low. Only descriptive analysis performed.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG000","title":"Cohort 1: Rhabdomyosarcoma (RMS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG001","title":"Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG002","title":"Cohort 3: Ewing Sarcoma/pPNET (Ewing)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG003","title":"Cohort 4 (Osteosarcoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG004","title":"Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG005","title":"Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG006","title":"Cohort 7 (Hepatoblastoma)"}],"paramType":"MEAN","populationDescription":"Biomarker set. Only patient with steady state trough plasma Pazopanib concentration included in the analysis.","reportingStatus":"POSTED","timeFrame":"predose Cycle 1 Day 1, Cycle 2 Day 1","title":"Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort","type":"SECONDARY","unitOfMeasure":"picogram/milliliter (pg/mL)"}